Английская Википедия:HU-210

Материал из Онлайн справочника
Версия от 11:09, 18 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 400102655 | IUPAC_name = (6a''R'',10a''R'')-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6''H'',6a''H'',7''H'',10''H'',10a''H''-benzo[''c'']isochromen-1-ol | image = HU-210 structure.svg | image2 = Hu210_bns.png...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox HU-210 is a synthetic cannabinoid that was first synthesized in 1988 from (1R,5S)-myrtenol[1] by a group led by Raphael Mechoulam at the Hebrew University.[2][3][4] HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[5] HU-210 has a binding affinity of 0.061 nM at CB1 and 0.52 nM at CB2 in cloned human cannabinoid receptors[6] compared to delta-9-THC of 40.7 nM at CB1. [7] HU-210 is the (–)-1,1-dimethylheptyl analog of 11-hydroxy- Δ8- tetrahydrocannabinol; in some references it is called 1,1-dimethylheptyl- 11-hydroxytetrahydrocannabinol. The abbreviation "HU" stands for Hebrew University.

Effects and research

HU-210, the (–) enantiomer of 11-OH-D8-THC-DMH, has almost all of the cannabinoid activity, while the (+) enantiomer, known as HU-211, is inactive as a cannabinoid and instead acts as an NMDA antagonist having neuroprotective effects.[8][9]

HU-210 has an oral LD50 of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits.[10] HU-210 has an LDLO (Lowest Lethal Dose amount) of 143 mg/kg in humans.[10] Delta-8-THC LD50 has not been confirmed. In a 1973 study monkeys and dogs given 9,000 mg/kg of delta-8-THC was nonlethal.[11][12]

Chemistry

HU-210 is the enantiomer of HU-211 (dexanabinol). The original synthesis of HU-210 is based on an acid-catalyzed condensation of (–)-Myrtenol and 1,1-Dimethylheptylresorcinol (3,5-Dihydroxy-1-(1,1-dimethylheptyl)benzol).[1]

HU-210 synthesis
HU-210 synthesis

Legal status

HU-210 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[13] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-210.

New Zealand

HU-210 is banned in New Zealand as of 8 May 2014.[14]

United States

HU-210 is not explicitly listed in the list of scheduled controlled substances in the USA.[15] A brief profile of HU-210 written and published by the Drug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under the Controlled Substances Act due to being similar to THC.[16] A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website.[17] In that PDF, DEA reasserts that HU-210 is a Schedule I substance. DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’. HU-210’s DEA No. is 7370; the same number assigned to dronabinol and synthetic Delta-8-THC.[18]

Alabama

HU-210 is a Schedule I controlled substance in Alabama.[19] Шаблон:Quote

Florida

HU-210 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.[20] Шаблон:Cquote

Vermont

Effective January 1, 2016, HU-210 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[21]

Other HU Cannabinoids

Шаблон:Colbegin

Шаблон:Colend

See also

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

Шаблон:Cannabinoids Шаблон:Hallucinogens Шаблон:Cannabinoidergics